BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Date and Time: January 6, 2026, 8AM ET Webcast: ...
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
New contributions to the field of epilepsy have opened a window into the cellular events that occur in the brain during absence seizures. At first, the teacher described her six-year-old student as ...
CHARLOTTESVILLE, Va. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced today that their first ...
(NewsNation) — March 26 is Purple Day, a day dedicated to raising awareness about epilepsy worldwide. An estimated 50 million people worldwide are diagnosed with epilepsy, and seizures are the main ...
A particular structure in the brain is a "choke point" for a type of epileptic seizure that affects mostly children, Stanford University School of Medicine investigators have found. The researchers ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
Scientists have discovered a neurological origin for absence seizures--a type of seizure characterized by very short periods of lost consciousness in which people appear to stare blankly at nothing.
The first seizure clinic model enabled rapid diagnosis and treatment for children with epilepsy, according to data presented ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback